PARP1 and cancer: In combination with the UPLC–HRAM-PRM assay used in this study, the removal of CDEAH adducts from the genome can be analyzed to study the kinetics of the NER and PARP1-dependent BER pathways in various DNA repair-deficient cell lines as well as cancer cells.